Pharmacological management of progressive-fibrosing interstitial lung diseases: A review of the current evidence

Luca Richeldi, Francesco Varone, Miguel Bergna, Joao de Andrade, Jeremy Falk, Robert Hallowell, Stéphane Jouneau, Yasuhiro Kondoh, Lee E. Morrow, Winfried Randerath, Mary Strek, Gabriela Tabaj

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a progressive-fibrosing phenotype, which is associated with a deterioration in lung function and early mortality. In addition to idiopathic pulmonary fibrosis (IPF), fibrosing ILDs that may present a progressive phenotype include idiopathic nonspecific interstitial pneumonia, connective tissue disease-associated ILDs, hypersensitivity pneumonitis, unclassifiable idiopathic interstitial pneumonia, ILDs related to other occupational exposures and sarcoidosis. Corticosteroids and/or immunosuppressive therapies are sometimes prescribed to patients with these diseases. However, this treatment regimen may not be effective, adequate on its own or well tolerated, suggesting that there is a pressing need for efficacious and better tolerated therapies. Currently, the only approved treatments to slow disease progression in patients with IPF are nintedanib and pirfenidone. Similarities in pathobiological mechanisms leading to fibrosis between IPF and other ILDs that may present a progressive-fibrosing phenotype provide a rationale to suggest that nintedanib and pirfenidone may be therapeutic options for patients with the latter diseases. This review provides an overview of the therapeutic options currently available for patients with fibrosing ILDs, including fibrosing ILDs that may present a progressive phenotype, and explores the status of the randomised controlled trials that are underway to determine the efficacy and safety of nintedanib and pirfenidone.

Original languageEnglish (US)
Article number180074
JournalEuropean Respiratory Review
Volume27
Issue number150
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Interstitial Lung Diseases
Pharmacology
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Phenotype
Therapeutics
Extrinsic Allergic Alveolitis
Connective Tissue Diseases
Occupational Exposure
Immunosuppressive Agents
Sarcoidosis
Disease Progression
Adrenal Cortex Hormones
Fibrosis
Randomized Controlled Trials
Safety
Lung
Mortality
pirfenidone
nintedanib

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Richeldi, L., Varone, F., Bergna, M., de Andrade, J., Falk, J., Hallowell, R., ... Tabaj, G. (2018). Pharmacological management of progressive-fibrosing interstitial lung diseases: A review of the current evidence. European Respiratory Review, 27(150), [180074]. https://doi.org/10.1183/16000617.0074-2018

Pharmacological management of progressive-fibrosing interstitial lung diseases : A review of the current evidence. / Richeldi, Luca; Varone, Francesco; Bergna, Miguel; de Andrade, Joao; Falk, Jeremy; Hallowell, Robert; Jouneau, Stéphane; Kondoh, Yasuhiro; Morrow, Lee E.; Randerath, Winfried; Strek, Mary; Tabaj, Gabriela.

In: European Respiratory Review, Vol. 27, No. 150, 180074, 01.01.2018.

Research output: Contribution to journalReview article

Richeldi, L, Varone, F, Bergna, M, de Andrade, J, Falk, J, Hallowell, R, Jouneau, S, Kondoh, Y, Morrow, LE, Randerath, W, Strek, M & Tabaj, G 2018, 'Pharmacological management of progressive-fibrosing interstitial lung diseases: A review of the current evidence', European Respiratory Review, vol. 27, no. 150, 180074. https://doi.org/10.1183/16000617.0074-2018
Richeldi, Luca ; Varone, Francesco ; Bergna, Miguel ; de Andrade, Joao ; Falk, Jeremy ; Hallowell, Robert ; Jouneau, Stéphane ; Kondoh, Yasuhiro ; Morrow, Lee E. ; Randerath, Winfried ; Strek, Mary ; Tabaj, Gabriela. / Pharmacological management of progressive-fibrosing interstitial lung diseases : A review of the current evidence. In: European Respiratory Review. 2018 ; Vol. 27, No. 150.
@article{63bb92dd652e4a5c9e89d493a1b2f0f3,
title = "Pharmacological management of progressive-fibrosing interstitial lung diseases: A review of the current evidence",
abstract = "A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a progressive-fibrosing phenotype, which is associated with a deterioration in lung function and early mortality. In addition to idiopathic pulmonary fibrosis (IPF), fibrosing ILDs that may present a progressive phenotype include idiopathic nonspecific interstitial pneumonia, connective tissue disease-associated ILDs, hypersensitivity pneumonitis, unclassifiable idiopathic interstitial pneumonia, ILDs related to other occupational exposures and sarcoidosis. Corticosteroids and/or immunosuppressive therapies are sometimes prescribed to patients with these diseases. However, this treatment regimen may not be effective, adequate on its own or well tolerated, suggesting that there is a pressing need for efficacious and better tolerated therapies. Currently, the only approved treatments to slow disease progression in patients with IPF are nintedanib and pirfenidone. Similarities in pathobiological mechanisms leading to fibrosis between IPF and other ILDs that may present a progressive-fibrosing phenotype provide a rationale to suggest that nintedanib and pirfenidone may be therapeutic options for patients with the latter diseases. This review provides an overview of the therapeutic options currently available for patients with fibrosing ILDs, including fibrosing ILDs that may present a progressive phenotype, and explores the status of the randomised controlled trials that are underway to determine the efficacy and safety of nintedanib and pirfenidone.",
author = "Luca Richeldi and Francesco Varone and Miguel Bergna and {de Andrade}, Joao and Jeremy Falk and Robert Hallowell and St{\'e}phane Jouneau and Yasuhiro Kondoh and Morrow, {Lee E.} and Winfried Randerath and Mary Strek and Gabriela Tabaj",
year = "2018",
month = "1",
day = "1",
doi = "10.1183/16000617.0074-2018",
language = "English (US)",
volume = "27",
journal = "European Respiratory Review",
issn = "0905-9180",
publisher = "European Respiratory Society",
number = "150",

}

TY - JOUR

T1 - Pharmacological management of progressive-fibrosing interstitial lung diseases

T2 - A review of the current evidence

AU - Richeldi, Luca

AU - Varone, Francesco

AU - Bergna, Miguel

AU - de Andrade, Joao

AU - Falk, Jeremy

AU - Hallowell, Robert

AU - Jouneau, Stéphane

AU - Kondoh, Yasuhiro

AU - Morrow, Lee E.

AU - Randerath, Winfried

AU - Strek, Mary

AU - Tabaj, Gabriela

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a progressive-fibrosing phenotype, which is associated with a deterioration in lung function and early mortality. In addition to idiopathic pulmonary fibrosis (IPF), fibrosing ILDs that may present a progressive phenotype include idiopathic nonspecific interstitial pneumonia, connective tissue disease-associated ILDs, hypersensitivity pneumonitis, unclassifiable idiopathic interstitial pneumonia, ILDs related to other occupational exposures and sarcoidosis. Corticosteroids and/or immunosuppressive therapies are sometimes prescribed to patients with these diseases. However, this treatment regimen may not be effective, adequate on its own or well tolerated, suggesting that there is a pressing need for efficacious and better tolerated therapies. Currently, the only approved treatments to slow disease progression in patients with IPF are nintedanib and pirfenidone. Similarities in pathobiological mechanisms leading to fibrosis between IPF and other ILDs that may present a progressive-fibrosing phenotype provide a rationale to suggest that nintedanib and pirfenidone may be therapeutic options for patients with the latter diseases. This review provides an overview of the therapeutic options currently available for patients with fibrosing ILDs, including fibrosing ILDs that may present a progressive phenotype, and explores the status of the randomised controlled trials that are underway to determine the efficacy and safety of nintedanib and pirfenidone.

AB - A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a progressive-fibrosing phenotype, which is associated with a deterioration in lung function and early mortality. In addition to idiopathic pulmonary fibrosis (IPF), fibrosing ILDs that may present a progressive phenotype include idiopathic nonspecific interstitial pneumonia, connective tissue disease-associated ILDs, hypersensitivity pneumonitis, unclassifiable idiopathic interstitial pneumonia, ILDs related to other occupational exposures and sarcoidosis. Corticosteroids and/or immunosuppressive therapies are sometimes prescribed to patients with these diseases. However, this treatment regimen may not be effective, adequate on its own or well tolerated, suggesting that there is a pressing need for efficacious and better tolerated therapies. Currently, the only approved treatments to slow disease progression in patients with IPF are nintedanib and pirfenidone. Similarities in pathobiological mechanisms leading to fibrosis between IPF and other ILDs that may present a progressive-fibrosing phenotype provide a rationale to suggest that nintedanib and pirfenidone may be therapeutic options for patients with the latter diseases. This review provides an overview of the therapeutic options currently available for patients with fibrosing ILDs, including fibrosing ILDs that may present a progressive phenotype, and explores the status of the randomised controlled trials that are underway to determine the efficacy and safety of nintedanib and pirfenidone.

UR - http://www.scopus.com/inward/record.url?scp=85058916693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058916693&partnerID=8YFLogxK

U2 - 10.1183/16000617.0074-2018

DO - 10.1183/16000617.0074-2018

M3 - Review article

C2 - 30578333

AN - SCOPUS:85058916693

VL - 27

JO - European Respiratory Review

JF - European Respiratory Review

SN - 0905-9180

IS - 150

M1 - 180074

ER -